<DOC>
	<DOCNO>NCT01179672</DOCNO>
	<brief_summary>The purpose trial ass efficacy duloxetine 60 milligram ( mg ) daily ( QD ) compare placebo , change pain severity baseline 12 week measure weekly mean daily pain score record participant 's diary participant diabetic peripheral neuropathic pain .</brief_summary>
	<brief_title>A Study Participants With Diabetic Peripheral Neuropathic Pain China</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Present pain due bilateral peripheral neuropathy Participants must pain caused Type 1 Type 2 diabetes mellitus Pain must begin foot relatively symmetrical onset Daily pain present least 6 month Diagnosis must confirm score least 3 Michigan Neuropathy Screening Inventory ( MNSI ) Females must test negative serum pregnancy test Screening . Females childbearing potential ( surgically sterilize menarche 1 year postmenopause ) must agree use medically acceptable reliable mean birth control , study 1 month follow last study dose . Stable glycemic control assess physician investigator glycosylated hemoglobin ( HbA1c ) &lt; 12 % randomization Score great equal 4 Brief Pain Inventory ( BPI ) 24hour average pain item Screening . Full completion daily diary least 80 % day second third time come hospital ( Screening ) . Currently enrol , discontinue within last 30 day , clinical trial involve investigational drug device offlabel use drug device , concurrently enrol type medical research judge scientifically medically compatible study Current ( less equal 1 year ) Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) Axis I diagnosis major depressive disorder , dysthymia , anxiety disorder ( exclude phobia ) , alcohol eat disorder determine MiniInternational Neuropsychiatric Interview ( MINI ) previous diagnosis DSMIV diagnosis mania , bipolar disorder , psychosis determine either participant history diagnosis use specific MNSI module Serious unstable cardiovascular , hepatic , renal , respiratory , hematologic illness , symptomatic peripheral vascular disease , medical condition psychological condition opinion investigator would compromise participation likely lead hospitalization course study . At Screening alanine transaminase ( ALT ) great 2 time upper limit normal ( ULN ) , base central laboratory reference range time ULN , base central laboratory reference range Prior renal transplant , current renal dialysis , serum creatinine laboratory value &gt; 1.5 time ULN , base central laboratory reference range Screening . Historical exposure drug know cause neuropathy , history medical condition , include pernicious anemia hypothyroidism , could responsible neuropathy Pain clearly differentiate condition interfere assessment diabetic neuropathy pain . Examples painful condition could confuse diabetic neuropathy pain include peripheral vascular disease , neurological disorder unrelated diabetic neuropathy , skin condition area neuropathy could alter sensation , painful condition Participants previously complete withdrawn study previously treat duloxetine , include participant participate study F1JMCHMEQ ( NCT00408993 ) , even placebo arm Participants take excluded medication stop Screening Treatment monoamine oxidase inhibitor ( MAOI ) fluoxetine within 30 day third Screening Participants positive Hepatitis B surface antigen and/or Hepatitis C antibody exclude following : Hepatic dysfunction determine investigator Clinical manifestation liver disease within previous year unexplained pruritus , unexplained dark urine , jaundice , unexplained right upper quadrant tenderness , unexplained `` flulike '' symptom Aspartate transaminase ( AST ) , ALT , bilirubin normal reference range .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Diabetic Peripheral Neuropathic Pain</keyword>
</DOC>